BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31926820)

  • 1. Elective Pelvic Nodal Irradiation With a Simultaneous Hypofractionated Integrated Prostate Boost for Localised Prostate Cancer: Ready for Prime Time?
    Cheung P; Niazi T; Faria S; Loblaw A
    Clin Oncol (R Coll Radiol); 2020 Mar; 32(3):181-188. PubMed ID: 31926820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience.
    Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM
    J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
    Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
    Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Image-guided Intensity-modulated Radiotherapy for Prostate Cancer Employing Hypofractionation and Simultaneous Integrated Boost: Results of a Consecutive Case Series with Focus on Erectile Function.
    Girelli G; Franco P; Sciacero P; Cante D; Borca VC; Pasquino M; Annoscia S; Tofani S; La Porta MR; Ricardi U
    Anticancer Res; 2015 Jul; 35(7):4177-82. PubMed ID: 26124375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial.
    Mendez LC; Arifin AJ; Bauman GS; Velker VM; Ahmad B; Lock M; Venkatesan VM; Sexton TL; Rodrigues GB; Chen J; Schaly B; Warner A; D'Souza DP
    BMC Cancer; 2020 Oct; 20(1):978. PubMed ID: 33036579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer.
    Mallick I; Das A; Arunsingh M
    Clin Oncol (R Coll Radiol); 2019 Apr; 31(4):260-264. PubMed ID: 30718087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidental Dose to Pelvic Nodal Regions in Prostate-Only Radiotherapy.
    Murthy V; Lewis S; Sawant M; Paul SN; Mahantshetty U; Shrivastava SK
    Technol Cancer Res Treat; 2017 Apr; 16(2):211-217. PubMed ID: 27492806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.
    Glicksman RM; Loblaw A; Morton G; Szumacher E; Chung HT; Vesprini D; Chu W; Liu SK; Choo R; Deabreu A; Mamedov A; Zhang L; Cheung P
    Radiother Oncol; 2021 Oct; 163():21-31. PubMed ID: 34324914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
    Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial.
    Magli A; Moretti E; Tullio A; Giannarini G; Tonetto F; Urpis M; Crespi M; Foti C; Prisco A; Polsinelli M; De Giorgi G; Bravo G; Scalchi P; Trovò M
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):269-276. PubMed ID: 29520019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
    Habl G; Katayama S; Uhl M; Kessel KA; Edler L; Debus J; Herfarth K; Sterzing F
    BMC Cancer; 2015 Nov; 15():868. PubMed ID: 26547188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients.
    Marvaso G; Jereczek-Fossa BA; Vischioni B; Ciardo D; Giandini T; Hasegawa A; Cattani F; Carrara M; Ciocca M; Bedini N; Villa S; Morlino S; Russo S; Zerini D; Colangione SP; Panaino CMV; Fodor C; Santoro L; Pignoli E; Valvo F; Valdagni R; De Cobelli O; Orecchia R
    Tumori; 2017 May; 103(3):314-318. PubMed ID: 28009421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated radiation therapy for prostate cancer: The McGill University Health Center experience.
    Barbosa Neto O; Souhami L; Faria S
    Cancer Radiother; 2015 Oct; 19(6-7):431-6. PubMed ID: 26278988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer.
    Franzese C; Fogliata A; D'Agostino GR; Di Brina L; Comito T; Navarria P; Cozzi L; Scorsetti M
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1301-1309. PubMed ID: 28271215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
    Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward.
    Kaidar-Person O; Roach M; Créhange G
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):600-5. PubMed ID: 23523182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.